comparemela.com
  1. Home
  2. Live Updates
  3. Blue Earth Diagnostics - Breaking News

Latest Breaking News On - Blue earth diagnostics - Page 8 : comparemela.com

Blue Earth Diagnostics and PETNET Solutions Inc, A Siemens Healthineers Company, Announce U S Commercial Availability of POSLUMA (Flotufolastat F 18) Injection for PET Imaging of Prostate Cancer

POSLUMA is now commercially available in multiple U.S. radiopharmacies, with nationwide availability by end of June 2023 

United statesDavide gaudenBarry scottSiemens healthineers companySociety of nuclear medicineDrug administration onBlue earth diagnostics ltdSolutions incBlue earth diagnosticsProstate specific membrane antigenDrug administrationNew drug applicationChief executive officerMedicare advantage plansEarth diagnosticsNuclear medicine

FDA Approves First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

The FDA has approved flotufolastat F 18 injection for positron emission tomography of prostate-specific membrane antigen–positive lesions in certain men with prostate cancer.

United statesDavide gaudenBlue earth diagnosticsBlue earth diagnosticBlue earth diagnostic poslumaEarth diagnosticsProstate cancer

U S FDA Approves Blue Earth Diagnostics POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

POSLUMA will be commercially available in the United States in early June 2023 

United statesScintomics gmbDavidm schusterShelby moneerDavide gaudenBrianf chapinWinship cancer institute of emory universityEmory university school of medicineDivision of surgeryDrug administrationUniversity of texas md anderson cancer centerA siemens healthineers companyDepartment of urologyTechnical university of munichSolutions incBlue earth diagnostics

FDA Approves Imaging Agent With Radiohybrid Technology to Identify Location, Extent of Prostate Cancer

The radiohybrid imaging agent allowed positron emission tomography to identify prostate cancer with an 83% detection rate.

United statesBrianf chapinDavidm schusterDavide gaudenDivision of surgeryDepartment of urologyUniversity of texas md anderson cancer centerWinship cancer institute at emory universityEmory university school of medicineBlue earth diagnosticsAdobe stockCancer centerEmory university schoolWinship cancer institute

U S FDA Approves Blue Earth Diagnostics POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

- POSLUMA will be commercially available in the United States in early June 2023 - Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative

United kingdomUnited statesClare gidleyMike beyerPriscilla harlanShelby moneerDavidm schusterBrianf chapinScintomics gmbDavide gaudenTechnical university of munichNuclear medicineDrug administrationDepartment of urologyEmory university school of medicineCorporate communications

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.